DEA Wants More Cannabis Grown And Fewer Opioids Produced In 2019. Seriously.

https://pixabay.com/photos/marijuana-grow-room-cannabis-hemp-1281540/

The Drug Enforcement Administration (DEA) isn’t exactly known as big fan of marijuana. But in a new Federal Register filing set to be published soon, the anti-drug agency is moving to more than quintuple the amount of cannabis that can legally be grown in the U.S. for research purposes—from roughly 1,000 pounds in 2018 to more than 5,400 pounds next year.

At the same time, DEA is also pushing to reduce the amount of certain opioid drugs—such as oxycodone, hydrocodone, morphine, fentanyl and others—that are produced in the U.S.

https://pixabay.com/photos/marijuana-grow-room-cannabis-hemp-1281540/
source

“We’ve lost too many lives to the opioid epidemic and families and communities suffer tragic consequences every day,” DEA Acting Administrator Uttam Dhillon said in a press release. “This significant drop in prescriptions by doctors and DEA’s production quota adjustment will continue to reduce the amount of drugs available for illicit diversion and abuse while ensuring that patients will continue to have access to proper medicine.”

US Attorney General Jeff Sessions, an adamant rival of marijuana ratification, added that “the opioid epidemic that we are facing today is the worst drug crisis in American history… Cutting opioid production quotas by an average of ten percent next year will help us continue that progress and make it harder to divert these drugs for abuse.”

The suggested distributions for cannabis and other drugs “reflects the total amount of controlled substances necessary to meet the country’s medical, scientific, research, industrial, and export needs for the year and for the establishment and maintenance of reserve stocks,” the DEA said.

The 2,450,000 grams of marijuana the agency wants the US to grow in 2019 is a significant jump from the 443,680 grams the agency authorized for 2018.

https://www.findclearchoice.com/dea-decision-cannabis-schedule-1-drug/dea-cannabis-schedule-1-drug/
source

“While the drastic increase in requested production of marijuana by the DEA is a positive sign, significant barriers still exist including but not limited to the NIDA monopoly on cultivation and undue hurdles for researchers to qualify for a permit,” NORML Political Director Justin Strekal said in an interview. “It’s time that Congress look at the 28,000 plus peer-reviewed studies currently hosted on the National Institute of Health’s online database and reform federal law by removing marijuana from the Controlled Substances Act all together.”

  • Subscribers who show their support with purchasing cannabis seeds or organic CBD products from our shop, help us keep doing this. Thank you for your support and for helping us improve!

  • 66
    Shares
0 0 vote
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments

Zenpype©

Zenpype Cannabis News Feed
0
Would love to hear your thoughts...x